SynthesisBMC cancer2025
Narrow-margin hepatectomy combined with external beam radiotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Feasibility Study of Combined Systemic Therapy and Carbon-Ion Radiotherapy for Hepatocellular Carcinoma Patients.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is still controversy regarding which adjuvant treatment should be used after hepatectomy to reduce recurrence and prolong survival. This study aims to compare the short-term and long-term outcomes between narrow margin hepatectomy combined with external beam radiotherapy (EBRT) and narrow margin hepatectomy alone in hepatocellular carcinoma (HCC) patients. PATIENTS AND
methodsWe conducted comprehensive searches in PubMed, Embase, the Cochrane Library, and Web of Science from database inception to March 2025. Eligible studies were those comparing narrow-margin hepatectomy with EBRT versus narrow-margin hepatectomy alone in HCC patients and reporting recurrence or survival. Meta-analysis was subsequently performed to pool data and assess therapeutic efficacy.
resultsThe analysis included eight studies with 1,057 patients, of whom 461 underwent narrow-margin hepatectomy with EBRT and 596 underwent narrow-margin hepatectomy alone. For disease-free survival (DFS), The pooled HRs (hazard ratios) was 0.6(95% CI: 0.49–0.74). The pooled ORs (odds ratios) for 1-, 3-, and 5-year outcomes were 2.47 (95% confidence interval [CI]: 1.75–3.49), 2.00 (95% CI: 1.52–2.63), and 2.20 (95% CI: 1.63–2.96), respectively. For overall survival (OS), the pooled HRs was 0.68(95% CI: 0.52–0.88). The pooled ORs for 1-, 3-, and 5-year outcomes were 3.86 (95% CI: 1.88–7.96), 1.97 (95% CI: 1.42–2.74), and 1.73 (95% CI: 1.29–2.33), respectively. In terms of recurrence, the OR for intrahepatic recurrence was 0.57 (95% CI: 0.42–0.78) in the EBRT combination group, while the OR for extrahepatic recurrence was 0.60 (95% CI: 0.37–0.96). Subgroup analyses showed that the combined treatment provided a significant advantage in all but two subgroup, which demonstrated a non-significant trend. Sensitivity analyses confirmed that these pooled results were robust. A total of 17 cases (4.42%) of grade 3 adverse events (AEs) were reported, with no grade ≥ 4 AEs observed.
conclusionThis study indicates that narrow-margin hepatectomy combined with adjuvant EBRT can reduce tumor recurrence and prolong survival in HCC patients. However, additional high-quality RCTs evaluating this combined strategy are required for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.